Harvard Medical School-ko ikertzaileekin lankidetzan egindako argitalpenak (3)

2023

  1. Enasidenib vs conventional care in older patients with late-stage mutant-IDH2 relapsed/refractory AML: a randomized phase 3 trial

    Blood, Vol. 141, Núm. 2, pp. 156-167

  2. IGLV3-21R110 mutation has prognostic value in patients with treatment-naive chronic lymphocytic leukemia

    Blood Advances

2010

  1. International network of cancer genome projects

    Nature, Vol. 464, Núm. 7291, pp. 993-998